pimobendan has been researched along with Cardiomyopathy, Dilated in 30 studies
pimobendan: produces arterial & venous dilatation in dogs; structure given in first source
Cardiomyopathy, Dilated: A form of CARDIAC MUSCLE disease that is characterized by ventricular dilation, VENTRICULAR DYSFUNCTION, and HEART FAILURE. Risk factors include SMOKING; ALCOHOL DRINKING; HYPERTENSION; INFECTION; PREGNANCY; and mutations in the LMNA gene encoding LAMIN TYPE A, a NUCLEAR LAMINA protein.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pharmacokinetics and pharmacodynamics of pimobendan were studied in eight patients with dilated cardiomyopathy and chronic congestive heart failure after single dosing and after 2-week repeated dosing of 5 mg racemic pimobendan." | 7.69 | Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing. ( Chu, KM; Hu, OY; Shieh, SM, 1995) |
| "Pimobendan (UD-CG 115 BS) was administered orally to 23 patients with congestive heart failure (functional class IV) caused by coronary artery disease (11 patients) or idiopathic dilated cardiomyopathy (12)." | 7.67 | Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. ( Brand, HJ; Hagemeijer, F; van Mechelen, R, 1989) |
| "Pimobendan was beneficial regardless of HF stage, but increased sudden cardiac death in end-stage HF with extensive remodelling of Ca(2+) handling." | 5.42 | Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure. ( Arioka, M; Kurebayashi, N; Li, L; Morimoto, S; Murayama, T; Nonaka, M; Sasaguri, T; Takahashi-Yanaga, F; Wang, YY; Yoshihara, T, 2015) |
| " The patient was treated for congestive heart failure because of dilated cardiomyopathy with furosemide, enalapril, pimobendan and l-carnitine." | 3.80 | Diagnosis and treatment of congestive heart failure secondary to dilated cardiomyopathy in a hedgehog. ( Delk, KW; Eshar, D; Garcia, E; Harkin, K, 2014) |
| "Pharmacokinetics and pharmacodynamics of pimobendan were studied in eight patients with dilated cardiomyopathy and chronic congestive heart failure after single dosing and after 2-week repeated dosing of 5 mg racemic pimobendan." | 3.69 | Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing. ( Chu, KM; Hu, OY; Shieh, SM, 1995) |
| "Pimobendan (UD-CG 115 BS) was administered orally to 23 patients with congestive heart failure (functional class IV) caused by coronary artery disease (11 patients) or idiopathic dilated cardiomyopathy (12)." | 3.67 | Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. ( Brand, HJ; Hagemeijer, F; van Mechelen, R, 1989) |
| "pimobendan (UDCG 115 BS) were studied by right and left heart catheterizations in patients suffering from idiopathic dilated cardiomyopathy (NYHA II and III)." | 2.67 | [Reduction in left ventricular volume and improvement in hemodynamics following intravenous administration of pimobendan (UDGG 115 BS) in dilated cardiomyopathy]. ( Busch, U; Lutilsky, L; Permanetter, B; Sebening, H, 1990) |
| "Pimobendan is a drug with both inotropic and vasodilatory properties and is widely used for the treatment of heart failure in dogs." | 2.46 | Current use of pimobendan in canine patients with heart disease. ( Boswood, A, 2010) |
| "Eleven cases of dilated cardiomyopathy have been diagnosed and treated in captive Livingstone fruit bats ( Pteropus livingstonii) in the United Kingdom over the past 7 yr." | 1.46 | MEDICAL MANAGEMENT OF DILATED CARDIOMYOPATHY IN LIVINGSTONE FRUIT BATS ( PTEROPUS LIVINGSTONII). ( Barbon, AR; Barrows, M; Borgeat, K; Day, C; Drane, AL; Hayward, N; Killick, R; Naylor, A; Routh, A; Saunders, R; Sewell, D; Studies, PGCEA; Wilkie, L, 2017) |
| "Pimobendan was beneficial regardless of HF stage, but increased sudden cardiac death in end-stage HF with extensive remodelling of Ca(2+) handling." | 1.42 | Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure. ( Arioka, M; Kurebayashi, N; Li, L; Morimoto, S; Murayama, T; Nonaka, M; Sasaguri, T; Takahashi-Yanaga, F; Wang, YY; Yoshihara, T, 2015) |
| "Pimobendan is an inotropic and vasodilating drug with phosphodiesterase (PDE) III-inhibiting and calcium-sensitizing effects." | 1.31 | Beta-blocker therapy combined with low-dose pimobendan in patients with idiopathic dilated cardiomyopathy and chronic obstructive pulmonary disease: report on two cases. ( Kajimoto, K; Kasanuki, H; Kawana, M; Matsuda, N; Shiga, T; Wakaumi, M; Yajima, T, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (36.67) | 18.7374 |
| 1990's | 6 (20.00) | 18.2507 |
| 2000's | 5 (16.67) | 29.6817 |
| 2010's | 7 (23.33) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Vigneault, A | 1 |
| Mylniczenko, ND | 1 |
| Arnold, RD | 1 |
| Jasper-Trotter, SL | 1 |
| Summa, N | 1 |
| Rousseau, C | 1 |
| Vergneau-Grosset, C | 1 |
| Killick, R | 1 |
| Barbon, AR | 1 |
| Barrows, M | 1 |
| Routh, A | 1 |
| Saunders, R | 1 |
| Day, C | 1 |
| Studies, PGCEA | 1 |
| Naylor, A | 1 |
| Hayward, N | 1 |
| Sewell, D | 1 |
| Borgeat, K | 1 |
| Drane, AL | 1 |
| Wilkie, L | 1 |
| Delk, KW | 1 |
| Eshar, D | 1 |
| Garcia, E | 1 |
| Harkin, K | 1 |
| Nonaka, M | 1 |
| Morimoto, S | 2 |
| Murayama, T | 1 |
| Kurebayashi, N | 1 |
| Li, L | 1 |
| Wang, YY | 2 |
| Arioka, M | 1 |
| Yoshihara, T | 1 |
| Takahashi-Yanaga, F | 2 |
| Sasaguri, T | 2 |
| Duchaussoy, AC | 1 |
| Day, J | 1 |
| Hughes, D | 1 |
| Boswood, A | 2 |
| Martin, MW | 1 |
| Stafford Johnson, MJ | 1 |
| Strehlau, G | 1 |
| King, JN | 1 |
| Hambrook, LE | 1 |
| Bennett, PF | 1 |
| Shiga, T | 2 |
| Wakaumi, M | 2 |
| Yajima, T | 1 |
| Kajimoto, K | 1 |
| Matsuda, N | 2 |
| Kawana, M | 1 |
| Kasanuki, H | 2 |
| Naganuma, M | 1 |
| Tatami, S | 1 |
| Summerfield, N | 1 |
| Dukes-McEwan, J | 1 |
| Swift, S | 1 |
| Patteson, M | 1 |
| Wotton, P | 1 |
| Martin, M | 1 |
| Johnson, M | 1 |
| Fuentes, VL | 1 |
| French, A | 1 |
| Culshaw, G | 1 |
| Little, C | 1 |
| Smith, P | 1 |
| Smith, S | 1 |
| Willis, R | 1 |
| Du, CK | 1 |
| Nishii, K | 1 |
| Minakami, R | 1 |
| Ohta, M | 1 |
| Tadano, N | 1 |
| Lu, QW | 1 |
| Zhan, DY | 1 |
| Mochizuki, M | 1 |
| Kita, S | 1 |
| Miwa, Y | 1 |
| Iwamoto, T | 1 |
| Ohtsuki, I | 1 |
| Solaro, RJ | 1 |
| Hagemeijer, F | 2 |
| Chu, KM | 1 |
| Shieh, SM | 1 |
| Hu, OY | 1 |
| Shiraishi, M | 1 |
| Murayama, K | 1 |
| Hanzawa, K | 1 |
| Warabi, K | 1 |
| Kamiyama, Y | 1 |
| Fujita, T | 1 |
| Tsuda, T | 1 |
| Nonaka, R | 1 |
| Miyajima, T | 1 |
| Tanaka, Y | 1 |
| Kodama, M | 1 |
| Izumi, T | 1 |
| Shibata, A | 1 |
| Thierfelder, L | 1 |
| Holubarsch, CH | 1 |
| Hasenfuss, G | 6 |
| Just, HJ | 1 |
| Permanetter, B | 6 |
| Sebening, H | 3 |
| Busch, U | 1 |
| Lutilsky, L | 2 |
| Baumann, G | 4 |
| Ningel, K | 2 |
| Holubarsch, C | 5 |
| Heiss, HW | 4 |
| Allgeier, M | 1 |
| Just, H | 5 |
| Hartmann, F | 2 |
| Klein, G | 2 |
| von Herrath, M | 1 |
| Wirtzfeld, A | 1 |
| Günes, S | 1 |
| Stinshoff, M | 1 |
| Rattert, B | 1 |
| Brand, HJ | 1 |
| van Mechelen, R | 1 |
| Heiss, WH | 1 |
1 review available for pimobendan and Cardiomyopathy, Dilated
| Article | Year |
|---|---|
Current use of pimobendan in canine patients with heart disease.
Topics: Animals; Cardiomyopathy, Dilated; Cardiotonic Agents; Dog Diseases; Dogs; Female; Heart Diseases; Ma | 2010 |
6 trials available for pimobendan and Cardiomyopathy, Dilated
| Article | Year |
|---|---|
Plasma concentration profile of orally administered pimobendan and plasma brain natriuretic peptide level in patients with severe heart failure.
Topics: Administration, Oral; Cardiomyopathy, Dilated; Cardiotonic Agents; Heart Failure; Humans; Natriureti | 2003 |
[Reduction in left ventricular volume and improvement in hemodynamics following intravenous administration of pimobendan (UDGG 115 BS) in dilated cardiomyopathy].
Topics: Adult; Cardiac Volume; Cardiomyopathy, Dilated; Cardiotonic Agents; Dose-Response Relationship, Drug | 1990 |
Cardiovascular profile of UDCG 115 BS-pimobendane and reversibility of catecholamine subsensitivity in severe congestive heart failure secondary to idiopathic dilated cardiomyopathy.
Topics: Blood Pressure; Cardiac Output; Cardiomyopathy, Dilated; Catecholamines; Dobutamine; Heart Failure; | 1989 |
Clinical efficacy of pimobendan (UD-CG 115 BS) in patients with chronic congestive heart failure.
Topics: Adult; Blood Pressure; Cardiac Output; Cardiomyopathy, Dilated; Cardiotonic Agents; Chronic Disease; | 1989 |
Acute effects of intravenous UD-CG 115 BS (pimobendan) on the cardiovascular system and left ventricular pump function.
Topics: Cardiomyopathy, Dilated; Cardiotonic Agents; Dose-Response Relationship, Drug; Double-Blind Method; | 1989 |
[Acute and chronic effects of UDCG 115 BS (pimobendan) in patients with advanced myocardial failure].
Topics: Adult; Aged; Cardiac Output; Cardiomyopathy, Dilated; Cardiotonic Agents; Clinical Trials as Topic; | 1989 |
23 other studies available for pimobendan and Cardiomyopathy, Dilated
| Article | Year |
|---|---|
MANAGEMENT OF SUSPECTED DILATED CARDIOMYOPATHY WITH PIMOBENDAN IN TWO LEOPARD SHARKS (
Topics: Animals; Body Weight; Cardiomyopathy, Dilated; Cardiotonic Agents; Male; Pyridazines; Sharks | 2023 |
MEDICAL MANAGEMENT OF DILATED CARDIOMYOPATHY IN LIVINGSTONE FRUIT BATS ( PTEROPUS LIVINGSTONII).
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Zoo; Cardiomyopathy, Dilated; Cardiotoni | 2017 |
Diagnosis and treatment of congestive heart failure secondary to dilated cardiomyopathy in a hedgehog.
Topics: Animals; Cardiomyopathy, Dilated; Cardiotonic Agents; Carnitine; Drug Therapy, Combination; Heart Fa | 2014 |
Stage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure.
Topics: Animals; Calcium Channels, L-Type; Calcium Signaling; Cardiomyopathy, Dilated; Cardiotonic Agents; D | 2015 |
What Is Your Diagnosis? Dilated cardiomyopathy.
Topics: Animals; Cardiomyopathy, Dilated; Cardiotonic Agents; Cat Diseases; Cats; Diuretics; Dobutamine; Fur | 2015 |
Canine dilated cardiomyopathy: a retrospective study of prognostic findings in 367 clinical cases.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Breeding; Cardiomyopathy, Dilated; Cardiotonic Ag | 2010 |
Effect of pimobendan on the clinical outcome and survival of cats with non-taurine responsive dilated cardiomyopathy.
Topics: Animals; Cardiomyopathy, Dilated; Cardiotonic Agents; Cat Diseases; Cats; Female; Humans; Male; Pyri | 2012 |
Beta-blocker therapy combined with low-dose pimobendan in patients with idiopathic dilated cardiomyopathy and chronic obstructive pulmonary disease: report on two cases.
Topics: Adrenergic beta-Antagonists; Cardiomyopathy, Dilated; Drug Therapy, Combination; Humans; Male; Middl | 2002 |
Preclinical dilated cardiomyopathy in the dobermann.
Topics: Animals; Cardiomyopathy, Dilated; Cardiotonic Agents; Dog Diseases; Dogs; Female; Male; Pyridazines; | 2006 |
Knock-in mouse model of dilated cardiomyopathy caused by troponin mutation.
Topics: Amino Acid Sequence; Animals; Calcium; Cardiomyopathy, Dilated; Cardiotonic Agents; Cell Membrane Pe | 2007 |
Translational medicine with a capital T, troponin T, that is.
Topics: Amino Acid Sequence; Animals; Calcium; Cardiomyopathy, Dilated; Cardiotonic Agents; Cell Membrane Pe | 2007 |
Hemodynamic performance during exercise in patients with severe chronic congestive heart failure before and after a single dose of pimobendan.
Topics: Administration, Oral; Aged; Cardiomyopathy, Dilated; Cardiotonic Agents; Child; Exercise; Female; He | 1994 |
Pharmacokinetics and pharmacodynamics of enantiomers of pimobendan in patients with dilated cardiomyopathy and congestive heart failure after single and repeated oral dosing.
Topics: Administration, Oral; Analysis of Variance; Cardiomyopathy, Dilated; Cardiotonic Agents; Echocardiog | 1995 |
[Epidural anesthesia for herniorrhaphy in a patient with severe dilated cardiomyopathy (DCM) under pimobendan control].
Topics: Anesthesia, Epidural; Cardiomyopathy, Dilated; Cardiotonic Agents; Dobutamine; Dopamine; Fentanyl; H | 1997 |
[A case of dilated cardiomyopathy with intractable heart failure treated with adjunctive therapy of pimobendan and denopamine].
Topics: Cardiomyopathy, Dilated; Chemotherapy, Adjuvant; Ethanolamines; Furosemide; Heart Failure; Humans; I | 1992 |
Myocardial energetics in dilated cardiomyopathy.
Topics: Adrenergic beta-Agonists; Cardiac Output; Cardiomyopathy, Dilated; Cardiotonic Agents; Coronary Circ | 1990 |
Effects of pimobendan on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy: comparison with nitroprusside.
Topics: Adult; Cardiomyopathy, Dilated; Cardiotonic Agents; Female; Hemodynamics; Humans; Male; Middle Aged; | 1989 |
Effect of intravenous pimobendan (UDCG 115 BS) on hemodynamics and left ventricular volumes in idiopathic dilative cardiomyopathy.
Topics: Adult; Aged; Blood Pressure; Cardiac Output; Cardiomyopathy, Dilated; Cardiotonic Agents; Dose-Respo | 1989 |
Coupling between myocardial oxygen consumption and mechanics in patients with dilative cardiomyopathy. Influence of vasodilation and positive inotropism.
Topics: Cardiomyopathy, Dilated; Cardiotonic Agents; Enoximone; Ferricyanides; Humans; Imidazoles; Myocardia | 1989 |
Influence of UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Cardiotonic Agents; Energy Metabolism; Female; Hemodynamics; Humans; Male; | 1989 |
Influence of the calcium-sensitizer UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. Comparison with nitroprusside.
Topics: Adult; Cardiomyopathy, Dilated; Cardiotonic Agents; Energy Metabolism; Female; Ferricyanides; Hemody | 1989 |
Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Topics: Administration, Oral; Aged; Cardiomyopathy, Dilated; Coronary Disease; Female; Heart Failure; Hemody | 1989 |
Influence of enoximone and UDCG-115 on coronary hemodynamics in idiopathic dilated cardiomyopathy.
Topics: Cardiomyopathy, Dilated; Coronary Circulation; Enoximone; Hemodynamics; Humans; Imidazoles; Myocardi | 1988 |